Emory licenses heart failure imaging technology to Syntermed
New ultrasound imaging software, which uses multiharmonic phase analysis (MHPA) to allow physicians to more accurately diagnose and treat heart failure patients, has been licensed by Emory University to Syntermed, an Atlanta-based nuclear medicine imaging and informatics software company.
The MHPA, developed by Emory medical scientists Ernest Garcia, PhD, and Ji Chen, PhD, in Atlanta, is designed to quickly determine which heart failure patients will benefit from cardiac resynchronization therapy (CRT). CRT is used to improve heart function by restoring the correct mechanical sequence of heart contractions in patients with an irregular heartbeat, called left ventricular dyssynchrony.
Syntermed will market the MHPA-based software as SyncTool, designed to provide improvements over TDI echo technology. Advances include additional image clarity, 3D perfusion images, an automated process that eliminates variations in interpretation, and rapid and objective physician assessment of dyssynchrony in heart failure patients, the company said.
SyncTool will be added as a new tool to the Emory Cardiac Toolbox.
The MHPA, developed by Emory medical scientists Ernest Garcia, PhD, and Ji Chen, PhD, in Atlanta, is designed to quickly determine which heart failure patients will benefit from cardiac resynchronization therapy (CRT). CRT is used to improve heart function by restoring the correct mechanical sequence of heart contractions in patients with an irregular heartbeat, called left ventricular dyssynchrony.
Syntermed will market the MHPA-based software as SyncTool, designed to provide improvements over TDI echo technology. Advances include additional image clarity, 3D perfusion images, an automated process that eliminates variations in interpretation, and rapid and objective physician assessment of dyssynchrony in heart failure patients, the company said.
SyncTool will be added as a new tool to the Emory Cardiac Toolbox.